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Abstract 
Title: Comparison of thiamine status in type II diabetes mellitus with and without lower 
extremity amputations: A prospective case control study 
Background: Diabetes Mellitus is quickly gaining the status of an epidemic in our country. 
The complications arising out of diabetes are one of the commonest problems encountered in 
the surgical outpatient clinics and the wards. Diabetic neuropathy along with 
microangiopathy predisposes the individual to development of diabetic ulcers which are 
treated with debridements or minor/major amputations depending upon the extent and 
severity of the lesion. Thiamine is a water soluble vitamin which takes part in the 
carbohydrate metabolism and is found to be deficient in chronic hyperglycaemic states. 
Thiamine and its synthetic derivatives have been shown to accelerate healing of ischemic 
diabetic limbs in animal models. Hence studies are required to determine and establish a 
correlation of diabetic patients undergoing lower extremity amputations and their thiamine 
levels. 
Aim: To assess the thiamine levels of patients undergoing lower limb amputations due to 
uncontrolled diabetes mellitus type II 
Study Design: Hospital based prospective case-control study 
Materials and Methods: A hospital based prospective case control study was done among 
the patients in the wards of the general surgical units. The cases were the patients with 
diabetes mellitus, who underwent lower extremity amputations. The controls were the 
patients in the wards of the general surgical units with diabetes mellitus who were otherwise 
healthy and did not undergo a lower extremity amputation. A one-on-one interview was 
conducted using a questionnaire detailing the patient demographics, anthropometrics and 
neurological examination. A blood sample was collected, under standard precautions, for the 
measurement of Erythrocyte Transketolase Activity (ETKA), and the value was recorded in 
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the data collection sheet. The routine investigations done for diabetic work-up were collected 
from the hospital medical records system and recorded on the data collection sheet. The 
normal range of Transketolase activity was deduced from the control arm of the study. 
Conclusion: The mean erythrocyte transketolase levels measured among the cases were 
lower than that for the control group but the difference was not statistically significant. 
Low thiamine levels were identified by using the mean value of the control arm as the 
lower limit of normal erythrocyte transketolase level. Using this value, sixty two percent 
of the cases were identified to have low thiamine levels. The low thiamine levels did not 
show any significant association with age, gender, body mass index or mode of diabetic 
treatment.  
The low thiamine levels were also compared to markers of glycaemic control and 
level of neuropathy among the cases. However, there was no significant correlation 
between the low thiamine levels and HbA1c, urinary micro-albumin and modified 
neuropathy disability score. Interestingly, the median neuropathy score among the cases 
(NDS=8) was significantly higher than that in the control arm (NDS=4). This was an 
important finding since a score of six or more was predictive of foot ulceration and 
subsequent risk of amputation, in the precious limb of the patients who had already 
undergone amputations of the contra-lateral limbs. Also the median urinary micro-
albumin among the cases (urine micro-albumin=70.5mg/mg of creatinine) was 
significantly higher than that among the controls (urine micro-albumin=17mg/mg of 
creatinine). The prevalence of abnormal urinary micro-albumin, suggestive of incipient 
diabetic nephropathy, was significantly high among cases (75%) as compared to the 
controls (33.3%). 
In view of the above, it is imperative that further role of thiamine should be investigated to 
establish a correlation between thiamine deficiency and complications of diabetes mellitus. 
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Introduction 
 
Diabetes Mellitus is one of the commonest illnesses that we come across in our 
outpatient clinics and the surgical wards. The complications of uncontrolled diabetes are a 
cause of significant morbidity and mortality in our daily practice. 
Diabetes is rapidly gaining the status of an epidemic in India with more than 62 
million individuals currently diagnosed with the illness(1). At present estimates, the 
prevalence of diabetes will exceed more than 350 million worldwide, with the maximum 
increase in India(2).  In our country, the aetiology of diabetes is multifactorial and includes 
genetic factors coupled with environmental influences such as obesity associated with rising 
living standards, steady urban migration, and lifestyle changes(3). A study done by Indian 
Council of Medical Research shows that Tamil Nadu has the second highest prevalence of 
diabetes in our country with 4.8 million diagnosed cases(4) .Among individuals with 
diabetes, glycaemic control worsens with longer duration of the disease(5), with neuropathy 
being the most common complication(6). Poor glycaemic control is responsible for the 
development of diabetic myonecrosis (7) and muscle infarction(8). A combination of the 
afore-mentioned complications, results in development of ulcers on the lower extremities and 
subsequent superficial and deep soft tissue infections leading to major and minor 
amputations. 
 
Thiamine is a water soluble vitamin that plays a central role in carbohydrate 
metabolism. It is a key co-enzyme in the multi-enzyme complexes like pyruvate 
dehydrogenase and alphaketoglutarate dehydrogenase that take part in oxidative 
decarboxylation of carbohydrates. Thiamine deficiency was described in diabetic patients as 
early as 1987(9) showed decreased thiamine levels in diabetic outpatients who were not on 
thiamine supplements. They also hypothesized that marginal thiamine deficiency in diabetic 
12 
 
patients could be due to restricted intake of food-stuffs, reduced absorption, reduced storage 
capacity, mal-utilizations, increased metabolism or increased excretion of thiamine. One 
study showed a 75% decrease in plasma thiamine levels in patients with type II diabetes 
mellitus due to increased renal clearance and fractional excretion of thiamine(10). An animal 
study done by Rana Chakrabarti et al , showed improvement in the structural damage caused 
by oxidative stress in diabetic rats leading to tissue necrosis, by using a synthetic lipid soluble 
derivative of thiamine called benfotiamine(11). He showed that benfotiamine prevented 
further renal alteration caused by uncontrolled diabetes mellitus. Gadau et al showed an 
accelerated healing of ischemic diabetic limbs in streptozocin induced diabetic mice, on 
treatment with benfotiamine, by preventing ischemia induced toe-necrosis and improvement 
in hind limb perfusion and oxygenation, and restoration of endothelium-dependent 
vasodilatation(12).  
Erythrocyte Transketolase activity and Thiamine Pyrophosphate Effect are methods 
of determining thiamine deficiency. At present there are no prospective studies that have been 
carried out in India comparing the thiamine status of the diabetic population. 
Hence, thiamine poses as a potential contender for adjunctive therapy in management 
of diabetic foot complications, both in prevention of diabetic ulcers and for prevention of 
amputation in the contra-lateral limb after an amputation on one limb. The proposed study is 
a first prospective study of its kind conducted on diabetic patients in our institution for 
establishing a correlation between diabetic patients undergoing lower extremity amputations 
and their thiamine status. 
Rationale for the choice of cases and controls 
The studies done in the past for measurements of thiamine levels had compared diabetic 
outpatients with normal age matched volunteers(9,13) and shown a significant decrease in 
thiamine levels among diabetic patients. With evidence of improved healing of ischemic toe-
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necrosis in animal models on treatment with thiamine derivatives(12), the role of thiamine in 
development of foot ulcers in diabetic patients needed to be explored further. This was the 
first study in our country which compared thiamine levels in patients undergoing a lower 
extremity amputation (cases), with non-amputated diabetics (controls). 
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Aims and Objectives 
 
 Aims 
 
To assess the thiamine status of patients undergoing lower limb amputations due to 
uncontrolled diabetes mellitus type II. 
 
 Objectives 
 
1. To measure and compare the Erythrocyte Transketolase activity (ETKA) 
(functional marker of thiamine status) in type II diabetics undergoing lower 
extremity amputations with non-amputated type II diabetics. 
2. To analyse possible correlation of thiamine deficiency with markers of 
progression of diabetes mellitus. 
 
 Null Hypothesis  
 
The diabetic patients undergoing lower extremity amputations have no reduction in 
Erythrocyte Transketolase Activity (ETKA) as compared to diabetic patients without 
lower extremity amputations. 
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1. Diabetes Mellitus 
1.2 Introduction 
Diabetes Mellitus denotes a group of common metabolic diseases that share the phenotype of 
hyperglycaemia. Several types of diabetes are caused by a complex interaction of genes and 
environmental factors. On the basis of the aetiology of the diabetes, factors contributing to 
hyperglycaemia include reduced insulin secretion, decreased glucose utilization, and 
increased glucose production. The metabolic dys-regulation associated with diabetes causes 
secondary pathophysiologic changes in multiple organ systems that impose a heavy burden 
on the individual with diabetes and on the health care system. In India, diabetes is the leading 
cause of non-traumatic lower extremity amputations. It also predisposes to cardiovascular 
diseases. With a booming incidence worldwide, diabetes will be a leading cause of morbidity, 
and mortality in the foreseeable future. 
1.2 Classification 
Diabetes is classified according to the pathogenic process that causes hyper-glycaemia. The 
two broad types of diabetes are as follows: 
1. Type 1 or Insulin Dependent Diabetes Mellitus( IDDM ) 
2. Type 2 or Non-Insulin Dependent Diabetes Mellitus( NIDDM ) 
3. Others 
Type 1 diabetes is the result of complete or near total absence of insulin. Type 2 diabetes is a 
mixed group of disorders, characterised by different degrees of insulin resistance, impaired 
insulin secretion and increased glucose production. The third category consists of diabetes 
due to genetic defects of cell function ( for example MODY 1 to 6), genetic defects in the 
action of insulin, diseases of the exocrine pancreas, endocrinopathies ( example acromegaly, 
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glucagonoma, Cushing‟s syndrome), drugs ( example glucocorticoids, pentamidine, thiazides 
) and  infections ( example congenital rubella, coxsackievirus or cytomegalovirus ). 
1.3 Diagnosis 
The diabetic status of a person can be classified in to three different categories which are 
1. Normal glucose homeostasis – when the fasting glucose level is less than 100mg/dl, 
the post-prandial glucose level is less than 140mg/dl (following an oral glucose 
challenge) and HbA1C is less than 5.6%.  
2. Impaired glucose homeostasis – when the fasting glucose level is between 100 and 
125mg/dl, the post-prandial glucose level is between 140 and 199mg/dl (following an 
oral glucose challenge) and HbA1C is between than 5.7% and 6.4%. 
3. Diabetes Mellitus – when the fasting glucose level is more than 126mg/dl, the post-
prandial glucose level is more than 200mg/dl (following an oral glucose challenge) 
and HbA1C is less than 6.5%. 
The International Expert Committee with members appointed by the American Diabetes 
Association (ADA), the European Association for the Study of Diabetes (EASD) and the 
International Diabetes Federation (IDF) has issued diagnostic criteria for DM which is as 
follows: 
1. Symptoms of diabetes plus random blood glucose concentration 200 mg/dl or 
2. Fasting plasma glucose 126 mg/dl or 
3. HbA1C > 6.5% or  
4. Two-hour plasma glucose 200 mg/dl during an oral glucose tolerance test. 
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1.4 Risk factors and Screening 
The ADA recommends screening all individuals more than 45 years of age, every 3 years and 
screening individuals at an earlier age if they are overweight [body mass index (BMI) >25 
kg/m
2
] and have one additional risk factor for diabetes. The risk factors for diabetes are as 
follows: 
1. Family history of diabetes (i.e., parent or sibling with type 2 diabetes) 
2. Obesity (Body Mass Index of more than 25 kg/m2) 
3. Physical inactivity 
4. Previously identified with Impaired Fasting Glucose, Impaired Glucose Tolerance, or 
an A1C of 5.7–6.4% 
5. History of gestational diabetes mellitus(GDM) or delivery of baby >4 kg (9 lb) 
6. HDL cholesterol level <35 mg/dl and/or a triglyceride level >250 mg/dl. 
7. Polycystic ovary syndrome or acanthosis nigricans 
8. Hypertension (blood pressure 140/90 mmHg) 
9. History of cardiovascular disease 
1.5 Epidemiology 
Diabetes is rapidly gaining the status of a potential epidemic in our country. As of 2007, there 
were more than 62 million individuals in our country that were diagnosed to have 
diabetes(1,14). According to worldwide estimates made by Wild et al, the prevalence of 
diabetes mellitus is going to double from 171 million in 2000 to 366 million in 2030 with 
India having the maximum increase(14). In India, the aetiology of diabetes mellitus is multi-
factorial. It includes genetic factors coupled with environmental influences like(2): 
1. Obesity 
2. Rising living standards 
3. Steady Urban migration 
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4. Lifestyle changes. 
With respect to geographical distribution, estimates reveal that the prevalence of diabetes 
mellitus in rural population is only one-quarter of that of urban population countries in the 
Indian subcontinent including Bangladesh, Nepal, Bhutan, and Sri Lanka(3,14). A study 
conducted by the Indian Council of Medical Research suggests that Maharashtra(9.2million) 
and Tamil Nadu(4.8 million) are more affected than states of Northern India like Jharkhand 
(0.96 million) or Chandigarh (0.12 million)(3). More studies are needed in our country to 
highlight the cultural and ethnic trends and give a comprehensive understanding of the 
differences in diabetes aetiology between Indian and other ethnic groups within India. 
There is gross disparity in our country with respect to access to reliable screening methods, 
anti-diabetic medications and health benefits in urban population as compared to the rural 
population. Multiple factors like illiteracy, poverty, poor sanitation, food insecurity and 
dominance of communicable diseases add to the reasons for undermining and under-
prioritising the looming threat of diabetes(4), by policy makers and local governments in 
rural areas 
Obesity is a major independent risk factor in diabetes which has found sub-optimal research 
focus in our country(15). In spite of having lower obesity and overweight rates, India has a 
higher prevalence of diabetes compared to western data which suggests that diabetes mellitus 
may occur at a much lower body mass index (BMI) in Indians compared with 
Europeans(15,16). As a result, relatively lean Indian adults with lesser body mass index may 
be at equal risk as those who are obese. Additionally, Indians are genetically susceptible to 
the development of coronary artery disease (CAD) due to dyslipidaemia and low levels of 
high density lipoproteins (HDL)(17). Hence these determinants make Indians more prone to 
development of the complications of diabetes at an early age (20-40 years) compared with 
Caucasians (>50 years) and indicate that diabetes mellitus must be carefully screened and 
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monitored regardless of patient age within India(17). Inadequate glycaemic control, a factor 
that has been witnessed in the Indian diabetic population (18) is to blame for the micro- and 
macro-vascular changes that manifest with diabetes, and can predispose diabetic patients to 
other complications for instance diabetic myonecrosis(7) and muscle infarction(8). 
2. Biochemistry of Insulin 
2.1 Biosynthesis 
Insulin is produced by the beta cells of the pancreatic islets. Initially, the molecule is a single 
chain 86 amino acid long precursor polypeptide which is called as pre-proinsulin. Afterwards, 
proteolysis removes the amino-terminal signal peptide which gives rise to  proinsulin. 
Further, removal of 31-residue fragment results in the formation of C peptide and the A and 
B chains of insulin.  
2.2 Secretion 
The following metabolites regulate the secretion of insulin: 
1. Glucose 
2. Amino acids 
3. Ketones 
4. Various nutrients 
5. Gastro-intestinal peptides 
6. Neurotransmitters 
Among the above metabolites, insulin is the most important regulator. Glucose more than 
70mg/dl stimulates insulin synthesis by increasing protein translation and processing.  
2.3 Action 
About 50% of the insulin that enters the portal veins gets degraded by the liver. The rest of 
the insulin enters the systemic circulation from where it reaches the receptors on the target 
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sites. Once bound to its receptor, the insulin molecule stimulates tyrosine kinase activity, 
leading to receptor auto-phosphorylation, and the recruitment of intracellular signalling 
molecules, such as insulin receptor substrates. This action sets up a phosphorylation and de-
phosphorylation cascade which results in the metabolic and mitogenic effects of insulin. 
Insulin is an anabolic hormone which increases the storage of carbohydrates and fats and 
protein synthesis. Brain is the only tissue which consumes glucose in an insulin-independent 
manner. 
3. Complications of Diabetes Mellitus 
The complications of diabetes mellitus can be classified as:  
1. Acute 
2. Chronic 
3.1 Acute Complications 
The acute complications of diabetes mellitus are more common in individuals with type I 
Diabetes mellitus. The complications are as follows: 
 Diabetic keto-acidosis:  It is a condition with the patient presenting with symptoms of 
nausea/vomiting, thirst and abdominal pain. On examination, the patient would have 
tachycardia, dehydration or hypotension, tachypnoea or Kussmaul breathing and 
lethargy. The precipitating events are usually inadequate insulin administration, 
infection or infarction (cerebral, coronary, mesenteric or peripheral). 
 Hyperglycaemic hyperosmolar state: It is a condition with the patient presenting with 
symptoms of polyuria, loss of weight and diminished oral intake. On examination, the 
patient has altered mental status and dehydration. 
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3.2 Chronic Complications 
The chronic complications are a major cause of morbidity and mortality in the medical and 
surgical wards. The complications can be divided in to two broad types which are vascular 
and non-vascular. The vascular complications are as follows: 
3.2.1 Micro-vascular Complications: 
1. Neuropathy 
a. Sensory neuropathy 
b. Motor Neuropathy (mono or polyneuropathy) 
c. Autonomic Neuropathy 
2. Nephropathy 
3. Ophthalmopathy 
a. Retinopathy (proliferative / non-proliferative) 
b. Macular oedema 
3.2.2 Macro-vascular complications: 
1. Coronary Heart Disease 
2. Peripheral Arterial Disease 
3. Cerebrovascular Disease 
3.2.3 Other Complications 
1. Gastro-intestinal 
a. Gastro-paresis 
b. Diarrhea 
2. Genito-Urinary 
a. Diabetic Uropathy 
b. Sexual  Dysfunction 
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c. Susceptibility to Infections 
d. Cataract 
e. Glaucoma 
f. Peri-odontal Disease 
g. Hearing loss 
3.3 Mechanisms of Complications 
Chronic hyperglycaemia is one of the most important factors for development of 
complications of Diabetes Mellitus.  However the actual mechanism that leads to the diverse 
cellular and organ dysfunction is unknown. There were four theories that have been proposed 
to explain as to how hyperglycaemia leads to the chronic complications of Diabetes Mellitus.  
1. The first theory suggests that elevated intracellular glucose leads to the formation of 
Advanced Glycosylation End products (AGEs). These AGEs cause non-enzymatic 
glycosylation reactions of the proteins present in the intra-cellular space and extra-
cellular space and have been shown to have the following effects : 
a. Cross-linking of proteins like collagen and extracellular matrix proteins 
b. Accelerate atherosclerosis 
c. Promote glomerular dysfunction 
d. Reduce nitric oxide synthesis 
e. Induce endothelial dysfunction  
f. Alter extracellular matrix composition and structure 
2. The second theory advocates the observation that hyperglycaemia increases glucose 
metabolism via the sorbitol pathway. The elevated concentration of sorbitol has the 
following effects: 
a. Changes the redox potential of the cell  
b. Increases cellular osmolality 
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c. Generates reactive oxygen species 
3. The third theory supports the idea that chronic hyperglycaemia leads to excess 
formation of diacylglycerol which leads to the activation of Protein Kinase C or PKC. 
PKC alters the transcription of genes for, type IV collagen, fibronectin, contractile 
proteins, and extracellular matrix proteins in endothelial cells and neurons. PKC 
inhibitors are being studied in trials for treatment of diabetic nephropathy. 
4. The fourth theory recommends that chronic hyperglycaemia increases the flux 
through hexosamine pathway. This pathway generates fructose-6-phosphate which is 
substrate for O-linked glycosylation and proteoglycan production. The proposed 
increase in function of the hexosamine pathway alters the glycosylation of proteins 
like endothelial nitric oxide synthase.  
Overall, growth factors seem to play an essential role in some Diabetes related complications, 
and their production is augmented by most of these proposed pathways. For example, the 
Vascular endothelial growth factor (VEGF-A) is found to be elevated locally in proliferative 
diabetic retinopathy and decline after laser photocoagulation. 
4. Prevention of Complications of Diabetes 
The complications of diabetes mellitus are a source of grave concern for the health care 
professionals. Hence, the factors helping in prevention of these complications are a matter of 
constant research. The Diabetes Control and Complications Trial (DCCT) gave conclusive 
proof in 2014 that reduction in the chronic hyperglycaemia will prevent the early 
complications of Diabetes Mellitus type I, by randomizing 1400 individuals with Type I 
Diabetes Mellitus to either conventional or intensive diabetes management(19). The DCCT 
established that improvement of glycaemic control reduced non-proliferative and 
proliferative retinopathy (47% reduction), micro-albuminuria (39% reduction), clinical 
nephropathy (54% reduction), and neuropathy (60% reduction). 
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Another trial called „United Kingdom Prospective Diabetes Study (UKPDS)‟ studied the 
course of more than 5000 individuals with Diabetes Mellitus type 2 for more than 10 
years(20). In this study, newly diagnosed patients with Diabetes Mellitus Type II were 
randomized to two groups, one being intensive treatment with insulin and one of the oral 
hypoglycaemic agent( either a sulfonylurea or metformin) and the other being conventional 
treatment using diet modification and pharmacotherapy. The UKPDS established that each 
percentage point reduction in A1C was associated with a 35% decrease in micro-vascular 
complications. 
Another landmark finding of the UKPDS was that strict control of blood pressure 
considerably reduced both macro-vascular and micro-vascular complications(20). In fact, the 
advantageous effects of blood pressure control were more than the beneficial effects of 
glycaemic control. Lowering blood pressure to moderate goals (144/82 mmHg) decreased the 
risk of Diabetes-related mortality, stroke, micro-vascular end- points, retinopathy, and heart 
failure (risk reductions between 32 and 56%). 
4.1 Diabetic Neuropathy 
The diabetic neuropathies are mixed group, involving various parts of the nervous system that 
present with varied clinical manifestations. These neuropathies may be either focal or diffuse. 
The most frequently occurring, among the neuropathies are chronic sensorimotor distal 
symmetric polyneuropathy (DPN) and the autonomic neuropathies(21). 
The early acknowledgement and suitable management of neuropathy in the individual with 
diabetes is imperative because:  
1. Up to 50% of distal symmetric polyneuropathy may be asymptomatic, and 
individuals suffering from the same are at a risk of insensate injury to their feet. As 
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more than 80% of amputations follow a foot ulcer or injury, early diagnosis of „at- 
risk‟ individuals, providing education, and appropriate foot care may result in a 
decreased incidence of ulceration and therefore amputation.  
2. Autonomic neuropathy causes considerable morbidity and mortality, especially if 
cardiovascular autonomic neuropathy (CAN) is present. 
Definition of Diabetic Peripheral Neuropathy 
 At present the definition of DPN in clinical practice is “the presence of symptoms and/or 
signs of peripheral nerve dysfunction in people with diabetes after the exclusion of other 
causes”(22). This definition clarifies that not all patients suffering from peripheral nerve 
dysfunction have a neuropathy due to diabetes. Validation of the same can be verified with 
quantitative electrophysiology, sensory, and autonomic function testing.  
4.1.1 Types of Diabetic neuropathy 
1. Acute Sensory Neuropathy 
2. Chronic Sensory-motor Neuropathy 
Acute sensory neuropathy 
Acute sensory neuropathy is very uncommon and has a tendency to follow episodes of poor 
metabolic control (e.g., ketoacidosis) or sudden worsening in glycaemic control (aka, “insulin 
neuritis”), and is characterized by the acute onset of severe sensory symptoms with marked 
nocturnal exacerbation but few neurologic signs on examination of the legs. 
Chronic sensorimotor neuropathy 
This is the most frequently seen presentation of neuropathy in diabetes, and up to 50% of 
diabetics  may have symptoms, most commonly burning pain, stabbing or electrical 
sensations, paraesthesias, hyperesthesia, and deep aching pain. Neuropathic pain is 
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characteristically worse at night, and the symptoms are mostly experienced in the feet and 
lower limbs though in some cases the hands also may be affected. Since up to half the 
patients may not have symptoms, a diagnosis may only be made on examination or, as seen in 
in some cases, the patient come with a painless foot ulcer.  
Examination of the lower limb typically has sensory loss of vibration, pain, pressure and 
temperature perception (mediated by small and large fibres) and absent ankle reflexes. 
Frequently signs of peripheral autonomic (sympathetic) dysfunction are often seen and 
include a warm or cold foot, occasionally with distended veins on dorsum of foot (in the 
absence of obstructive peripheral vascular disease), dry skin, and the presence of calluses on 
pressure-bearing area 
The diagnosis of DPN can be made only after a thorough clinical examination, and all 
diabetic patients should be screened annually for DPN by examining temperature, pinprick, 
and vibration perception (using a 128-Hz tuning fork, see figure 1), 10-g monofilament 
pressure sensation at the distal halluces, and ankle jerk reflexes. Combinations of more than 
one test have >87% sensitivity in identifying DPN(21). Absence of 10-g monofilament 
perception and decreased vibration perception foretell foot ulcers. Also, longitudinal studies 
have revealed that a simple clinical examination is a good predictor of foot ulcer risk in the 
future(23). The feet should be regularly examined for calluses, ulcers and deformities, and the 
footwear should be inspected. Multiple scoring systems have been devised for monitoring the 
progression or response to intervention in clinical trials. 
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Figure 1 
 
Figure 2                                                                                                     Figure 3 
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Other forms of neuropathy, including B12 deficiency, chronic inflammatory demyelinating 
polyneuropathy (CIDP, hypothyroidism, and uraemia, occur more commonly in diabetes and 
should be excluded. 
 
4.2 Diabetic Foot Ulcers 
Diabetic foot pathologies like infections, ulcerations and gangrene, are the most common 
cause of hospitalization amongst the diabetic patients(24). McNeely and his colleagues 
postulated that the majority of foot ulcers resulted from minor trauma in the presence of 
sensory neuropathy(25). Even though the pathogenesis of diabetic peripheral sensory 
neuropathy is still not fully understood, there appears to be several mechanisms involved, 
including the generation of advanced glycosylated end products (AGEs) and diacyl-glycerol, 
oxidative stress as well as activation of protein kinase C β. Additionally, the Diabetes Control 
and Complications Trial(19) and other prospective trials have established the crucial role of 
hyperglycaemia in the onset and progression of neuropathy. The data connecting glycaemic 
control and neuropathy were not as well defined as those for retinopathy due to the difficulty 
in categorizing objective measures to gauge the many stages of neuropathy over time and also 
since the symptoms, or lack thereof, of neuropathy may be misleading if assessed only 
through patient questionnaires. 
4.3 Scoring systems in Diabetic Neuropathy 
Dyck and colleagues pioneered the use of composite scores to evaluate clinical signs of 
diabetic neuropathy(26,27). Their team described the diabetic neuropathy symptom score, 
neuropathy disability score (NDS) and later the Neuropathy Impairment Score (NIS). Several 
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large studies have used the modified NDS as shown in figure 4(23,28,29) and also, it can be 
used in the community by a trained non-specialist. 
 
 
Figure 4 Modified Neuropathy disability Score VPT – Vibration Perception Threshold.  
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5. Thiamine 
 
Thiamine or Vitamin B 1 has a quintessential role to play in the energy-generating 
metabolism and especially the metabolism of carbohydrate. It can exist in our body as 
thiamine monophosphate and thiamine diphosphate. Thiamine diphosphate( figure 6) is one 
of the co-enzymes in the three multi-enzyme complexes that catalyse oxidative 
decarboxylation reactions which are the following: 
1. Pyruvate dehydrogenase in carbohydrate metabolism 
2. Alpha – ketoglutarate dehydrogenase in citric acid cycle 
3. Branched chain keto-acid dehydrogenase involving the metabolism of valine, leucine 
or isoleucine.  
It is also useful as a co-enzyme in the pentose pathway for transketolase. In each of these 
complex pathways, the role of thiamine diphosphate is to provide a reactive carbon on the 
thiazole moiety that leads to formation of a carbanion( figure 7). This carbanion adds to the 
carbonyl group of pyruvate, alpha-ketoglutarate or the branched chain keto-acid as required 
in the respective complexes 
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Figure 5                                                                                                                   Figure 6 
. 
The discovery of thiamine dates back to the late 1890's, when the Dutch medical officers 
Eijkman and Grijns, who were working in Java, showed that a paralytic illness resembling 
beriberi could be produced in chickens by feeding them a diet solely consisting of polished 
rice(30). Human experiments were conducted in a mental asylum and in a railroad labour 
camp in the Malay States, where half of the subjects were fed polished rice, and the other half 
were given brown rice, from which the polishings hadn‟t been removed(31). Beriberi always 
manifested in the white rice groups.  
Jansen and Donath in 1926 isolated the anti-beriberi factor, vitamin B1, as crystals from a 
water extract of rice bran. In 1936, Williams identified and published the chemical formula 
and named it thiamine, referring to the amino and thiazole groups in the molecule.  One year 
later, improvement in the methods of synthesis led to the first commercial manufacture of the 
vitamin.   
5.1 Chemistry of Thiamine 
The thiamine molecule is white crystalline, water soluble solid. In the crystallized state or in 
an acidic medium the stability of thiamine is good, even on heating. In a neutral or alkaline 
medium, thiamine is unstable and sensitive to oxygen, heat and ultraviolet light. 
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Thiamine is a water-soluble vitamin and its absorption takes place in the jejunum. The 
absorption occurs via an active transport portal (when the thiamine levels in the small 
intestines are low) or via a passive mucosal process (when thiamine concentration is high). 
Phosphorylation of thiamine takes place in the small intestine(32) and gets converted to 
active co-enzyme thiamine pyrophosphate. The body itself cannot synthesize thiamine but 
can only store up to 30 mg of it in the tissues and is mostly concentrated in our skeletal 
muscles. The other organs, in which it is stored, are the brain, liver, heart and kidneys. 
Although all cell types use thiamine, the nervous system is especially sensitive to thiamine 
deficiency due to its role in the production of acetylcholine and γ-aminobutyric acid in our 
brain. Also the heart is extremely sensitive to thiamine deficiency due to the high level of 
oxidative metabolism. The half-life of thiamine is 9-18 days. Thiamine is excreted by kidneys 
and its rate is determined by its tubular reabsorption, glomerular filtration and also on plasma 
thiamine concentration(33).  
 
5.2 Intra-Cellular Thiamine Metabolism 
Thiamine and Thiamine Monophosphate are the most abundant forms found in the plasma. 
Uptake of thiamine and its monophosphate (TMP), by cells is mediated by particular 
thiamine transporters 1 (THTR1 encoded by SLC19A2 gene) and 2 (THTR2 encoded by 
SLC19A3) and RFC1 (Reduced Folate Carrier – 1). Most of thiamine in the cytoplasm 
(around 90%) is phosphorylated by TPK1 (Thiamine Phosphokinase) to TDP (Thiamine di 
phosphate) and used as a cofactor of cytoplasmic enzymes while the remaining thiamine 
stays un-phosphorylated(34). Most of the Thiamine Di-phosphate (approximately 90%) is 
transported into mitochondria through the thiamine transporter from the solute carrier group 
of proteins encoded by the SLC25A19 gene. The intracellular mechanism of thiamine is 
summarized in the figure 8 below (35) 
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Figure 7 
 
Since the body is unable to store thiamine and the vitamin has a great turnover rate, a 
constant supply of the vitamin is needed. The limited stores may be exhausted within two 
weeks or less on a thiamine-free diet, with clinical signs appearing shortly thereafter. The 
body is readily depleted of thiamine by fever and other metabolic stress. The heart, liver, 
kidney and brain have the highest levels, followed by the leukocytes and the red blood cells 
(F. Hoffman-LaRoche, 1994). De-phosphorylation can occur in the kidney and excess free 
vitamin is rapidly excreted in the urine. The urinary elimination depends partly on the urine 
volume and during diuresis large amounts of thiamine may be lost. Small quantities of 
thiamine are excreted in sweat. 
The foodstuffs rich in thiamine are the following(32): 
1. Whole-grain foods 
2. Meat/fish/poultry/eggs 
3. Tomato and orange juices 
4. Milk and milk products 
5. Legumes (like lentils, soybeans, nuts, seeds) 
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6. Vegetables (like green, leafy vegetables; beets; potatoes) 
The foodstuffs containing thiaminases, like milled rice, shrimp, fresh fish, mussels, clams and 
raw animal tissues, reduce the absorption of thiamine. 
 
5.3 Thiamine deficiency 
It is a clinical syndrome that arises as a result of either of the following factors: 
1. Lack of thiamine intake in the diet: 
a. Food having a elevated level of thiaminases, including milled rice, raw 
freshwater fish, ferns and raw shellfish. 
b. Consumption of foodstuffs high in anti-thiamine factor, like tea, coffee, or 
betel nuts. 
c. Processed food with high amounts of sulphite in it, which destroys thiamine. 
2. Diet-related factors causing reduced thiamine intake: 
a. Starvation state 
b. Alcoholic state 
c. Gastric bypass surgery - Due to limited caloric intake during postsurgical 
repair(36–38). 
d. Parental nutrition with insufficient thiamine supplementation(39). 
3. Increased consumption states: 
a. Hyperthyroidism(40) 
b. Pregnancy  
c. Diets high in carbohydrate or saturated fat intake 
d.  Lactation 
e. Fever - Severe infection/sepsis (41) 
f. Increased physical exercise 
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g. Re-feeding syndrome (carbohydrate metabolism is increased) 
4. Increased Depletion(13): 
a. Diarrhoea 
b. Diuretic therapies 
c. Peritoneal dialysis 
d. Haemodialysis/continuous renal replacement therapy 
e. Hyperemesis gravidarum 
It is expressed in the initial stages by anorexia, malaise, and weakness of the legs, often with 
paraesthesia; there may be slight oedema and palpitations. The disorder may continue in this 
chronic state or may at any time escalate to an acute condition characterized either by cardiac 
involvement with oedema or by peripheral neuropathy; forms intermediate between these two 
extremes may also exist. It is thought that the basic cause is the inhibition of a series of 
enzyme-catalysed cleavages of carbon-carbon bonds in which thiamine di-phosphate is a 
coenzyme. 
The deficiency is known as beriberi, Ceylon sickness, oriental beriberi or rice disease. The 
outbreaks of beriberi are commonly seen in displaced and refugee populations. Thiamine 
deficiency occurs mainly where the diet consists of milled white cereals, as well as polished 
rice, and wheat flour which are all very poor sources of thiamine. Thiamine deficiency can 
occur within 2-3 months of a poor intake and can cause disability and death. Thiamine 
deficiency in refugees has been reported in Thailand at the start of the 1980's and in the 
1990's, Djibouti (1993) in Guinea (1990), and in Nepal (1993-1995). 
In Europe, North America and Australia, thiamine deficiency is prevalent among alcoholics 
and typically manifests itself as the Wernicke-Korsakoff syndrome but has also been 
described in patients on controlled diets for obesity, those who received total parenteral 
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nutrition and in those who are on fad diets or whose intakes are high in carbohydrate and low 
in thiamine. 
5.4 Risk factors for thiamine Deficiency 
The great epidemics of thiamine deficiency in South-East Asia at the start of this century 
followed the large scale production of milled rice and its distribution. The availability of 
milled rice as an inexpensive and popular food in urban areas was also a reason for the 
occurrence of thiamine deficiency in these areas. The requirement of thiamine is amplified 
when carbohydrates are taken in large volumes and is higher during periods of increased 
metabolism which are: 
1. Fever 
2. Muscular activity 
3. Hyperthyroidism and  
4. During pregnancy and lactation 
 A diet based on polished rice is rich in carbohydrates which enhances the thiamine 
requirement and is worsened by low thiamine content. Rolfe and his colleagues deduced in 
1993 that the risk factors for thiamine deficiency were(42) 
1. Pregnancy 
2. Alcohol consumption 
3. Chronic disability 
4. Exercise 
5. Diabetes and  
6. Dysentery 
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5.5 Signs and Symptoms of Thiamine Deficiency 
Thiamine deficiency in adults can manifest as one of the following two syndromes which are: 
1. Thiamine deficiency with peripheral neuropathy 
2. Thiamine deficiency with cardiopathy 
5.5.1 Thiamine deficiency with Peripheral Neuropathy 
It is an acute type of thiamine deficiency categorized by polyneuropathy with paraesthesia of 
the extremities (mainly the legs), decreased knee jerk and other tendon reflexes, and 
progressive profound weakness and wasting of muscles and the vulnerability to infections is 
also increased. This syndrome is also known as dry beriberi, atrophic beriberi, endemic 
polyneuritis, pan-neuritis endemica, paralytic beriberi or polyneuritis endemica. 
Another distinct presentation of neurological involvement is Wernicke encephalopathy, in 
which an orderly sequence of symptoms, occurs which include vomiting, horizontal 
nystagmus, palsies of the ocular movements, fever, ataxia, and worsening mental impairment 
leading to Korsakoff syndrome(43–45). Treatment can be initiated at any stage by the 
addition of thiamine, unless the patient is in fulminant Korsakoff syndrome. Only half of the 
patients treated at this stage improve significantly. 
5.5.2 Thiamine deficiency with cardio-pathy 
An acute form of thiamine deficiency categorised by oedema (mainly of the legs, but also 
involving the trunk and the face), increased cardiac output, ventricular dysfunction, sinus 
rhythm, dilatation of arterioles, depressed erythrocyte and leukocyte transketolase, elevated 
serum lactates and pyruvates, and pulmonary congestion with pleural effusion. In this 
condition, death from congestive cardiac failure may occur abruptly. 
 A less common fulminant variant is summarized by lactic acidosis, hypotension, tachycardia, 
and pulmonary oedema (which eventually cause the death); this is labelled thiamine 
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deficiency with lactic acidosis. The other names for this condition are wet beriberi, beriberi 
heart disease, cardiovascular or Shoshin beriberi. 
The deficiency of thiamine is occasionally confounded by presence of symptoms of multiple 
deficiencies like Vitamin B, Vitamin C and other minerals. Many cases of thiamine 
deficiency show a combination of the above two described syndromes.  
5.6 Clinical Diagnostic Criteria for Thiamine Deficiency 
MSF/Epicentre (1992) defined a suspect case of thiamine deficiency as a person having at 
least two of the following signs: 
• Bilateral oedema of the lower limbs, 
• Dyspnoea with exertion or at rest, 
• Paraesthesias of the hands or feet or a symmetrical decrease in muscle strength or motor 
deficits: stepping or loss of balance. 
5.7 Biochemical detection of thiamine deficiency 
The diagnosis of beriberi can be done by a dietary history suggestive of a low thiamine intake 
and clinical signs. However, independent biochemical tests of thiamine status, particularly 
measurement of erythrocyte transketolase activity (ETKA) and thiamine pyrophosphate 
effect (TPPE), offer a sensitive test for thiamine deficiency where the laboratory facilities are 
available(46). 
Detection of free thiamine in the blood plasma does not necessarily reflect a direct 
relationship to the level in the body tissues. Erythrocyte or leucocyte thiamine values actually 
show a more accurate relationship to tissue content (47). Hence, erythrocyte transketolase 
activity, the activity of the thiamine-requiring enzyme transketolase, seems to provide 
information as to tissue reserves of thiamine and mirrors a direct functional assessment at the 
cellular level. The assay for transketolase or TPPE is performed in the presence and absence 
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of added thiamine and expressed as an activity coefficient. The values without additional 
thiamine reveal the amount of coenzyme present in the cells.  
The stimulation with further thiamine pyrophosphate gives the measure of apo-enzyme 
present that lacks coenzyme. Hence, the thiamine pyrophosphate effect or TPPE is expressed 
as the percentage rise in ETKA obtained after addition of Thiamine Pyrophosphate to the 
erythrocyte. The biochemical diagnostic criteria of thiamine deficiency is defined by low 
ETKA and high TPPE (Table 1)(48). 
Table 1 
 
Urinary thiamine levels can also offer information regarding the sufficiency of dietary 
intakes, but they don‟t provide information regarding the state of deficiency, or the extent of 
depletion of the tissue thiamine reserves. At recommended consumptions, urinary excretion 
of thiamine ranges from 40 to 90 micrograms per day. When intake is poor, urinary excretion 
falls below 25 micrograms per day. A link between the urinary excretion of thiamine per 
gram of Creatinine and thiamine intake has been observed. Table 2 summarizes the 
interpretive guidelines for the urinary excretion of thiamine(49). Analyses of 24-hour urine 
collections provided more consistent information than random sample collections. In 
clinically apparent cases of thiamine deficiency, the 24-hour urinary excretion of 0 to 15 
micrograms of thiamine had been reported(49). Further information as to the physiological 
state with respect to thiamine could be obtained from the test-dose procedure. The most 
commonly used procedure is to give 5 mg of thiamine parenterally and then measure the 
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urinary excretion of thiamine over the next 4-hour period (see Table). Although the test may 
not precisely identify clinical thiamine deficiency or point toward the severity of the 
deficiency, it can be used as an indicator of poor intakes and tissue deficits of the vitamin 
(49). 
Table 2 
 
Therefore, to summarize, the following methods of detection of thiamine deficiency can be 
carried out: 
1. Blood thiamine: Blood has only about 0.8% of the total body store of thiamine, and 
the concentration is too low to permit exact extrapolation of the total thiamine status.  
2. Urinary thiamine excretion: The estimation of urinary thiamine excretion is poorly 
reliable method for judging tissue stores, and similar to the blood levels, is really only 
a reflection of the immediately preceding intake. Clinical signs of deficiency have 
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been noted when less than 70micrograms of a 1 mg dose of thiamine is excreted in the 
urine in a dose-retention test(50). 
3. Pyruvate and lactate: Thiamine is necessary for pyruvate metabolism. Therefore, 
increased blood pyruvate and lactate levels can be triggered by thiamine deficiency. 
In thiamine deficiency, the fasting levels of blood pyruvate have often been found to 
be normal and only increase above the normal following a glucose load (51). The 
estimation of blood pyruvate could be of help in the diagnosis of suspected thiamine 
deficiency. But it is not appropriate for the detection of minimal thiamine deficiencies 
in view of restrictions in the sensitivity of this index. An elevated pyruvate level isn‟t 
always attributable to thiamine deficiency.  
4. Transketolase activity / thiamine pyrophosphate effect: One of the most dependable 
indicators of thiamine functional status is the activity of the thiamine-requiring 
enzyme trans-ketolase. The level of trans-ketolase activity allows for judgement on 
the availability of thiamine.  
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6. THIAMINE AND DIABETIC COMPLICATIONS 
Hyperglycaemia (the aggregate exposure to elevated glucose levels, as well as individual 
pattern of glucose variation) along with increased availability of free fatty acids (a 
consequence of unregulated lipolysis in adipose tissue as well as their “spill over” in case of 
adipocyte saturation in obese subjects) are the two main metabolic alterations characterising 
gluco-toxicity and lipo-toxicity in diabetes and are causally responsible for the development 
of vascular complications. 
Enhanced glucose supply fuels its intracellular metabolism (glycolysis) with subsequent 
increase in the generation of reactive oxygen species (ROS) in mitochondria(52,53) . 
Overproduction of these reactive oxygen species in mitochondria links hyperglycaemia with 
activation of several biochemical pathways involved in the development of micro vascular 
complications of diabetes which include hexosamine and polyol pathways, production of 
advanced glycation end products (AGEs) and activation of protein kinase C(54). It does so by 
inhibition of the key glycolytic enzyme glyceraldehyde3phosphate dehydrogenase. 
However, cells in our body are adept in either lowering the excess production of ROS by 
non-enzymatic and enzymatic antioxidant mechanisms and/or removal of damaging 
metabolites and their substrates (produced by excess glycolysis) that accumulate within cells. 
Pentose phosphate pathway (PPP) is an example of the second mechanism. PPP gives a 
substitute pathway for glucose oxidation accomplishing three important functions which 
are(35): 
1. Production of reducing equivalent NADPH required for decreasing oxidized 
glutathione thereby supporting intracellular antioxidant defence. 
2. Production of ribose-5-phosphate necessary for the synthesis of nucleotides. 
3. Metabolic use of Pentoses obtained from the diet. 
 
45 
 
The Pentose Phosphate Pathway has the following two branches: 
1. Irreversible oxidative branch required for pentose phosphates and NADPH 
production. 
2. Reversible non-oxidative branch in which inter-conversion of three to seven carbons 
containing sugars take place. 
Transketolase (TKT), one of the vital enzymes of non-oxidative branch of Pentose Phosphate 
Pathway, can limit the activation of harmful pathways by decreasing the availability of their 
precursors. Transketolase transports two carbon units and catalyses synthesis of ribose-5-
phosphate from intermediates of glycolytic pathway. Thiamine, as a cofactor of 
Transketolase, may have a great influence on glucose metabolism through the regulation of 
Pentose Phosphate Pathway and therefore, Transketolase activation by Thiamine in 
endothelial cells blocked numerous pathways responsible for hyperglycaemic injury and 
stopped the development and progression of diabetic complications in animal models(55). 
The fundamental tool responsible for the observed effect of thiamine or its derivative 
benfotiamine upon activation of non-oxidative reversible branch of Pentose Pathway was the 
diminished build-up of triose-phosphates and fructose-6-phosphate induced by 
hyperglycaemia(56). 
Plasma thiamine levels are decreased in diabetics by 75% as compared to healthy 
subjects(10).  The Reduced Folate Carrier (RFC1) and THTR1 protein expression in RBCs 
obtained from diabetic patients (both T1DM and T2DM) is higher than in normal healthy 
subjects(10). 
Experimental proof suggests anomalous thiamine handling in our kidneys in diabetes mellitus 
which might be one of the causes for reduced plasma thiamine levels in diabetics. Incubation 
of human primary proximal tubule cells in excess glucose conditions (26 mmol/L) reduces 
both mRNA and protein expression of THTR1 and THTR2 as compared to 5 mmol/L glucose 
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(57).  The renal clearance of thiamine is amplified 8-fold in experimental models of diabetes. 
Remarkably, increased clearance was prevented by high dose thiamine 
supplementation(58).The renal clearance of Thiamine was also increased in subjects with 
Type I Diabetes Mellitus by 24 fold  and Type 2 Diabetes Mellitus by 16fold(10) 
 
Additional changes in thiamine metabolism possibly occur with the development of chronic 
diabetic micro-vascular complications like diabetic nephropathy along with chronic kidney 
disease (CKD). Although in diabetics with intact renal function, the plasma thiamine levels 
tend to be decreased mostly due to elevated renal clearance, in subjects with CKD stages 
consistent with renal insufficiency and failure the situation dramatically changes. Plasma 
levels of thiamine and its esters and Erythrocyte TKT activity increased with severity of 
diabetic nephropathy (and CKD respectively) being maximum in subjects with end stage 
renal disease, however, levels of Thiamine Di-phosphate in RBCs did not show proportional 
trend. Since the effectiveness of intracellular Thiamine Di-Phosphate production relies on the 
substrate availability (i.e., the rate of trans-membrane transport via thiamine transporters) and 
Thiamine Pyrophosphokinase (TPK) activity, these could be the processes reduced by 
hyperglycaemia and the contributory reasons for the failure of protective action of Pentose 
phosphate pathway under hyperglycaemia(35). Although Type 1 and Type 2 Diabetic patients 
with normal kidney function have been shown to have an increased expression of THTR1 and 
THTR2 in mononuclear cells as compared to healthy subjects by one study (59), data on TPK 
activity and THTR2 expression in diabetes are still missing and warrant further study. 
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6.1 Supplementation of Thiamine in Human, Animal and In Vitro models in Diabetic 
Conditions 
6.1.1 Human Studies 
Very few studies have been published on diabetic patients till now, that elaborated the effect 
of thiamine or benfotiamine (the synthetic form of thiamine) treatment on definitive 
endpoints like the development or progression of clinically evident diabetic complications, 
i.e. kidney disease, ophthalmopathy and neuropathy. In the pilot study by Rabbani and his 
colleagues, high dose thiamine therapy given for 3 months significantly reduced urinary 
albumin excretion without altering glycaemic control, lipids and blood pressure in T2DM 
patients(60). Another study done by Alkhlef and his team however, showed that three months 
of benfotiamine therapy enhanced the thiamine status (assessed by the Transketolase activity 
and the whole blood thiamine levels) but did not change the urinary albumin excretion and 
kidney markers of tubular damage in patients with type 2 Diabetes Mellitus(61). The same 
team also assessed the production Advanced Glycosylation End production (AGEs) and 
markers of endothelial dysfunction and low grade inflammation in the same cohort of 
subjects. Benfotiamine did not alter any of the ascertained markers(62). In patients suffering 
from diabetic neuropathy, short term benfotiamine therapy was found to improve neuropathy 
score and to lower the pain perception(63). In a study done recently, long term (one year) 
benfotiamine supplementation therapy did not alter the peripheral nerve function and soluble 
markers of inflammation (like interleukin6 or E-selectin) in spite of significantly increasing 
the whole blood levels of thiamine and Thiamine Di-phosphate in patients with Type 1 
Diabetes Mellitus(64). This study was criticized for incorrect study design and the definition 
of its endpoints(64). 
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6.1.2 Animal Studies 
For animals, the first published study investigating the effect of supplementation of thiamine 
and benfotiamine on peripheral nerve function and generation of AGEs in diabetic rats 
discovered that benfotiamine but not thiamine had a protective effect on both processes(65). 
Hammes and his colleagues provided proof for the role of Pentose Phosphate Pathway in 
diabetes showing that benfotiamine (activating Transketolase) blocked three harmful 
pathways and NF-κ signalling triggered by hyperglycaemia and prevented progression of 
diabetic retinopathy in experimental rats(55). Thornalley and his group had published a series 
of articles exploring the effect of thiamine and/or benfotiamine supplementation on the 
development of diabetic micro-vascular complications, mainly diabetic kidney disease. They 
found that thiamine and its synthetic preparation were able to lower the accumulation of 
AGEs in the nerves, eyes, kidneys and plasma of diabetic rats(66). Moreover, they also 
reported that high dose benfotiamine and thiamine therapy prevented diabetic nephropathy 
due to the increased Transketolase expression, lowered level of triose-phosphates and 
decreased protein kinase C activation. Most notably, since no alterations in fasting plasma 
glucose and HbA1c were detected, this effect is independent of diabetic control(57).  
 
Moreover, high-dose thiamine therapy had positive effect on diabetes related dyslipidaemia 
(checking the increase of triglycerides and plasma cholesterol but not high density lipoprotein 
decrease). Low dose thiamine and Benfotiamine failed to achieve the same effect(67). They 
also measured AGEs in plasma of rats with induced diabetes. Both benfotiamine and 
thiamine supplementation have been shown to stabilize AGEs derived from methyl-glyoxal 
and glyoxal. On the other hand, carboxy-methyl lysine and N-epsilon( 1carboxyethyl) lysine 
residues were decreased by thiamine only(68). Finally, they calculated protein damage 
caused by oxidation, glycation, oxidation and nitration in diabetic rats and found elevated 
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content of AGEs in the diabetic nerve, eye, kidney and plasma that was reversed on 
administration of benfotiamine and thiamine. The increase of plasma glycation free adducts 
was also reversed by Thiamine. Administration of both thiamine and benfotiamine reversed  
the elevated urinary excretion of oxidation, glycation and nitration free adducts(69). Multiple 
studies investigated the effect of treatment with thiamine/benfotiamine with respect to cardiac 
function in diabetic animal models and found out that Benfotiamine improved abnormalities 
in parameters related to the contractile dysfunction in diabetic mice. In these studies, 
although the generation of AGEs did not change, the oxidative stress induced by diabetes was 
reduced(70). Kohda and his colleagues elaborated that high dose therapy with thiamine 
averted diabetes related cardiac fibrosis through amplified expression of genes with pro-
fibrotic effect and reduced matrix metalloproteinase activity in hearts of diabetic rats(71). 
Another study done by Katare and his team discovered that therapy with benfotiamine 
prevented cardiac failure in diabetic mice. There were several pathogenic mechanism 
suggested like 
 Improved cardiac perfusion  
 Reduced fibrosis  
 Cardio-myocyte apoptosis(72).  
The same team also found that benfotiamine enhanced prognosis of diabetic mice after a 
myocardial infarction with respect to functional recovery, survival, decreased cardio-myocyte 
apoptosis and neuro-hormonal activation(73). Similar results were also found in the control 
non-diabetic mice which were perhaps due to elevated activity of pyruvate dehydrogenase in 
the cardiac myocytes of diabetic rats on treatment with thiamine. Consequent in vitro 
experiment showed that the responsible molecular mechanism may be suppression of O-
glycosylated protein(74). Both in vitro and in vivo supplementation of benfotiamine had 
positive effect on cardiac progenitor cells in terms of their functionality, proliferation, 
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abundance and Transketolase activity (all listed parameters being compromised by 
hyperglycaemia)(75). In mice with induced diabetes with limb ischemia benfotiamine 
increased the Transketolase activity, prevented toe necrosis, enhanced perfusion and restored 
vasodilation.  Furthermore, benfotiamine prevented build-up of AGEs in blood vessels and 
inhibited pro-apoptotic caspase-3 in muscles(12). Another study investigated the cerebral 
oxidative stress in diabetic mice and reported that benfotiamine was found to decrease 
oxidative stress (as projected by reduced/oxidized glutathione). Although the levels of AGEs, 
protein carbonyl and tumour necrosis factorα remained unchanged(76). Therapy with 
benfotiamine and fenofibrate alone or in a combination decreased nephropathy and 
endothelial dysfunction in diabetic rats. The lipid profile of these rats, however were 
normalized only by administration of fenofibrate and not by benfotiamine(77) 
6.1.3 In Vitro Studies 
Numerous studies have investigated the effect of thiamine and/or benfotiamine on 
mechanisms associated with the pathogenesis of hyperglycaemia induced damage in vitro. 
Cultivation of erythrocytes in hyperglycaemia with addition of thiamine enhanced the activity 
of Transketolase enzyme, lowered production of triose phosphates and methyl-glyoxal and 
improved concentrations of sedoheptulose-7-phosphate and ribose-5-phosphate(78). 
Thiamine as well as Benfotiamine have been shown to correct faulty replication of human 
umbilical vein endothelial cells (HUVEC) and to lower their production of AGEs caused by 
hyperglycaemia(79). Thiamine also inhibited markers of endothelial cell dysfunction 
(supressed cell migration and improved von Willebrand factor secretion) caused by 
hyperglycaemia in bovine aortic endothelial cells(80). Addition of both benfotiamine and 
thiamine reduced activation of polyol pathway (aldose reductase mRNA expression, enzyme 
activity and intracellular levels of sorbitol) while increasing expression and activity of TKT 
in HUVEC and bovine retinal pericytes cultured in hyperglycemia[32]. Notably, 
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benfotiamine restored impairment of endothelial progenitor cells differentiation caused by 
hyperglycemia[33]. Possible benfotiamine antioxidant properties and protective effect on 
DNA have also been investigated. Benfotiamine prevented oxidative stress (probably through 
direct antioxidant effect) and also DNA damage[34]. The same study also confirmed that 
benfotiamine increased TKT expression and activity. Intermittent exposure of human retinal 
pericytes to fluctuating glucose levels induced their apoptosis, the effect was however 
prevented by thiamine and benfotiamine[35]. It has also been studied whether thiamine 
and/or benfotiamine affect glucose and lipid metabolism in human skeletal 
muscle cells. Benfotiamine but not thiamine increased glucose oxidation while lipid oxidation 
and metabolism was influenced by neither of the two. Benfotiamine also down regulated 
NADPH-oxidase-4 expression [36].  
Rationale for the choice of cases and controls 
The studies done in the past for measurements of thiamine levels had compared diabetic 
outpatients with normal age matched volunteers(9,13) and shown a significant decrease in 
thiamine levels among diabetic patients. With evidence of improved healing of ischemic toe-
necrosis in animal models on treatment with thiamine derivatives(12), the role of thiamine in 
development of foot ulcers in diabetic patients needed to be explored further. This was the 
first study in our country which compared thiamine levels in patients undergoing a lower 
extremity amputation (cases), with non-amputated diabetics (controls). 
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Materials and Methodology 
Source of Data:  
The study was conducted in the in-patient wards of Department of General 
Surgery, Christian Medical College, a tertiary care centre in Vellore, Tamil Nadu. 
This institute was established in the year 1990 and is now a 2700 bedded multi-
specialty hospital. The annual out-patients and in-patients handled were around 2.4 
million and 140,000 respectively. The diabetic patients who underwent lower 
extremity amputations were recruited as cases and the patients who had not 
undergone amputations were recruited as controls 
 
Key Criteria 
Inclusion Criteria 
1. For cases 
a. Type II Diabetes Mellitus for more than 5 years 
b. Age more than 30 years 
2. For Controls 
a. Type II Diabetes Mellitus more than 5 years 
b. Age more than  30 years 
3. Common inclusion: Individuals agreeing to participate in the study with 
written informed consent. 
Exclusion Criteria 
1. Alcohol consumption of more than 50 units per week 
2.  End stage renal disease 
3. Individuals who are already receiving thiamine supplements. 
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Methods 
A hospital based prospective case control study was done among the patients in the wards of 
the general surgical units. The cases were patients with diabetes mellitus, who were 
undergoing lower extremity amputations. The controls were patients in the wards of the 
general surgical units with diabetes mellitus who were otherwise healthy and did not undergo 
a lower extremity amputation. A one-on-one interview was conducted using a questionnaire 
detailing the patient demographics, anthropometrics and neurological examination. A blood 
sample was collected, using standard precautions, for measurement of Erythrocyte 
transketolase Activity, and the values were recorded in the data collection sheet.  
The routine investigations done for diabetic work-up were collected from the hospital 
medical records system and recorded in the data collection sheet.  
A sensory examination of the lower extremities was conducted for evaluation of neuropathy. 
This examination scored the individual based on the Neuropathy Disability Score which 
involved assessment of vibration perception threshold using a 128Hz tuning fork over the big 
toe, temperature sensation by placing a beaker of ice over the dorsum of foot and cutaneous 
pressure perception assessment using a Semmes-Weinstein monofilament followed by 
examination of the ankle reflex assessment. The individual would be scored on the basis of 
the Neuropathy Disability Score and classified as significant neuropathy (score of more than 
6 on 10) or insignificant neuropathy (score of less than 6 on 10). For patients with trans-
femoral or trans-tibial unilateral amputations, NDS was assessed in the contra lateral foot and 
the score was then doubled for statistical analysis.  
Outcomes 
The primary outcome studied was the difference between erythrocyte transketolase levels 
between the cases and controls. The secondary outcomes studied were the correlation of low 
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transketolase levels in cases with markers of glycaemic control of the patient and degree of 
neuropathy. 
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Sample size: 
 
The sample size was calculated using „n Master 2.0‟ software. To test the 
significant difference between the two groups (primary and secondary outcomes), 
the minimum required number of cases were approximately 26 in each group. So 
the total number of subjects needed for this study was 52. 
 
The variables in the above equation were calculated as below: 
Pooled standard deviation (σ) =3.2761 
Mean TPPE level in cases, μ1=16.160% 
Mean TPPE level in controls, μ2=13.610% 
Standard normal variate for 5% level of significance, Z1-/2 = 1.96 
Standard normal variate for 80% power, Z1-= 0.84 
The mean difference and pooled standard deviation values were taken from 
the literature: Kursat Dabak T. et al(2012). 
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Variables 
The variables studied were: 
1. Demography: 
 Age 
 Gender 
2. Details regarding diabetes mellitus 
 Duration of diabetes 
 Type of diabetic treatment whether: 
i. None  
ii. Oral hypoglycaemic drugs only 
iii. Insulin only 
iv. Oral hypoglycaemic drugs and insulin 
3. Presence of co-morbid illnesses: 
 Hypertension 
 Ischaemic Heart Disease 
 Dyslipidaemia 
4. Anthropometry 
 Height  
 Weight 
 Body Mass Index 
5. Type of Amputation among cases 
 Major i.e. trans-tibial or trans-femoral. 
 Minor i.e. ray amputation of digits or trans-metatarsal 
amputations 
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6. Modified Neuropathy disability Score 
 Vibration Perception threshold 
 Temperature perception on the dorsum of foot 
 Pin-Prick 
 Achilles Reflex 
7. Markers of glycaemic control 
 Fasting Blood Sugar 
 Post-Prandial Blood Sugar 
 Glycosylated Haemoglobin levels(HbA1c) 
 Urinary Micro-albumin 
 Serum Creatinine 
8. Thiamine levels calculated as Erythrocyte transketolase levels ( a 
surrogate marker of thiamine status). 
 Since there was no standard value in terms of erythrocyte 
transketolase activity in literature, the mean value among the 
control group was taken as the lower limit of normal and the 
low thiamine status was defined in the case group as subjects 
having an ETKA below the mean ETKA of the control group. 
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Statistical Analysis 
Data from the case report form was entered into the Epidata v 3.1 data 
entry software and then exported to SPSS. The analysis was performed by 
trained biostatisticians 
The data was analysed using the STATA I/C 13.1. All demographic and 
clinical variables were summarised as counts and percentages for categorical 
variables, mean and standard deviation for symmetrically distributed continuous 
variables and median and range for skewed continuous variables. Rank sum test was 
used to compare the categorical variables and Pearson correlation 
coefficient/Spearman‟s correlation co-efficient was used for continuous variables. 
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Results 
A total of 58 patients were recruited in this study between February 2016 and September 
2017 but only 48 samples were suitable for processing for erythrocyte transketolase activity. 
There were 24 patients each in the Case and control group respectively. The „Case‟ group 
were patients with diabetes mellitus who underwent a lower extremity amputation and the 
„Control‟ group were patients with diabetes mellitus who had not undergone a lower 
extremity amputation. 
Variables Case group Control group P Value 
Age Mean(SD) 54.6(10.9) 54.6(9.9) 0.99 
Gender  
Male (%) 16(66.67%) 17(70.83%) 
0.755 
Female (%) 8(33.33%) 7(29.17) 
Median Duration of Diabetes 8 10 0.96 
Type of treatment  
None 2 1 
0.551 
OHA only 12 14 
Insulin only 5 2 
OHA and Insulin 5 7 
Co-morbidities  
Hypertension(% of total) 7(29.17%) 7(29.17%) 1.000 
Ischaemic Heart Disease(% of 
total) 
3(12.5%) 0(0%) 0.074 
Dyslipidaemia(% of total) 3(12.5%) 1(4.17%) 0.296 
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Weight Mean(SD) 68.1(13.4) 67.9(10.2) 0.96 
Variables Case group Control group P Value 
Height Mean(SD) 161.5(9.48) 163.8(9.62) 0.14 
Body Mass Index Mean(SD) 26.4(4.1) 25.4(3.1) 0.31 
Fasting blood sugar(median) 
176 155 0.58 
Post prandial blood sugar(median) 
272 241 0.10 
HbA1c 
9.5 8.9 0.17 
Serum Creatinine 
0.8 0.9 0.36 
  
Demographic Data 
The baseline data comparing the Case group and control group are tabulated below. 
 Gender 
 
Figure 8 Comparison of Gender Distribution between cases and controls. 
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Sixty six percent of patients in the Case group were males and Seventy percent of 
Control group were males. There was no significant difference in the gender distribution 
between these two groups.  
 
 Age 
 
 
 
The above histogram shows the mean age of patients in Case group and Control group. 
The mean ages of patients in both groups were 54.6 years. 
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 Duration of Diabetes 
 
The above figure describes the median duration of diabetes in the cases and controls. The 
median duration in the case group was 8 years with minimum duration of 5 years and 
maximum duration of 16.5 years. . The median duration in the control group was 10 
years with minimum duration of 5 years and maximum duration of 17 years. 
Type of Treatment 
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66 
 
 
The above pie charts display the distribution of treatment taken by patients in the case 
group and control group. In both the groups the most common modality was oral 
hypoglycaemic drugs with 50% and 59% in case and control group, respectively 
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. 
 Neuropathy Disability Score 
 
 
The above clustered histogram shows the comparison of neuropathy disability score in 
the case and control group. The median score in Case group was 8 and in control group 
was 4. The difference was statistically significant with p value less than 0.001.  
 Urinary Micro-albumin 
 
Normal urinary microalbumin  
(less than 30mcg/mg creatinine) 
Increased Urinary micro-
albumin ( more than 30mcg/mg 
creatinine) 
P value 
Cases 6 18 
0.003 
Controls 16 8 
 
The above table shows the distribution of urinary micro-albumin among cases and controls. 
Seventy five percent of cases had abnormal urinary micro-albumin levels as compared to 
0
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68 
 
thirty three percent of controls with abnormal urinary micro-albumin levels with the 
difference being statistically significant (p value = 0.003). 
 
The above bar diagram demonstrates the comparison of urinary micro-albumin levels in the 
case and control groups. The median urinary micro-albumin excretion among the cases was 
70.5mcg/mg of Creatinine as compared to 17mcg/mg of Creatinine in the control group. The 
difference was statistically significant with p value of 0.001. 
 
 
 
 
 
 
 
 
70.5 
17 
0 20 40 60 80
Cases
Controls
Urinary Micro-albumin (mcg/mg of creatinine) 
Urinary Micro-albumin
(mcg/mg of creatinine)
69 
 
Type of Amputation 
 
 
 
The above chart shows the distribution of the type of amputation in the case group. 12 
out of 24 patients underwent minor amputations including trans-metatarsal and ray 
amputations. 12 out of 24 patients underwent major amputations including trans-tibial 
and trans-femoral amputations. 
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Type of Amputation 
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Co-morbid Illnesses 
 
Figure 9 Presence of comorbid conditions among the study subjects 
The above chart shows the distribution of co-morbid conditions among the subjects in 
the study. Hypertension (29.17%) was the most common co-morbid condition noted 
among the study subjects with 7 cases and 7 controls having hypertension. 
 
Erythrocyte trans-ketolase Activity 
Table 3 Comparison of erythrocyte transketolase activity among cases and controls.  
 
No. of 
Subjects 
Mean 
ETKA 
Standard 
deviation 
Median P - value 
Cases 24 78.18 22.45 78.33 
0.7997 
Controls 24 83.75 23.10 78.30 
 
The above table compares the erythrocyte transketolase activity (ETKA) between the case 
and the control group. The values were reported as concentration of enzyme x10
-3 
Nano gram 
29.17% 
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per Nano gram of protein. The mean ETKA in the case group was 78.18 x 10
-3 
ng/ng whereas 
the mean ETKA in the control group was 83.75 x 10
-3 
ng/ng. The median value in both 
groups was nearly similar with 78.33 x 10
-3 
ng/ng in the case group and 78.30 x 10
-3 
ng/ng in 
the control group. Since there was no standard value in terms of erythrocyte transketolase 
activity in literature, the mean value among the control group (83.75 x 10
-3 
ng/ng) was taken 
as the lower limit of normal and the low thiamine status was defined in the case group as 
subjects having an ETKA below the mean ETKA of the control group.  
 
 
 
Thiamine status in Cases 
 
Figure 10 Distribution of low thiamine among cases. 
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The above pie chart depicts the distribution of low thiamine levels among the cases. Sixty 
two percent of the patients in the case group had low thiamine levels as compared to the 
thirty seven percent of patients who had a normal thiamine levels.  
 
 Low thiamine Percentage 
Males 8 50% 
Females 7 87.5% 
 
The above table shows the distribution of low thiamine levels among the cases. Fifty percent 
of the male patients had low thiamine levels whereas eighty seven percent of the females had 
low thiamine levels.  
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Modified Neuropathy Disability Score 
 
Figure 11 Distribution of Low thiamine levels among cases with normal and high neuropathy disability score. 
The above histogram describes the distribution of low thiamine levels with respect to the 
neuropathy disability score. A score of more than 6 is predictive of foot ulceration and 
subsequent amputation. Among the cases with high neuropathy disability score (i.e. >6) 14 
subjects had low thiamine levels and 8 subjects had normal thiamine levels.  One subject 
each with normal NDS had low and normal thiamine levels. The correlation with thiamine 
and neuropathy disability score was not significant with p value being 0.703. 
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Type of Amputations 
Table 4 Table with distribution of low thiamine levels in different categories of amputations 
Type of Amputation Low thiamine Normal thiamine P Value 
Major 9 3 
0.206 
Minor 6 6 
 
The above table describes the distribution of low thiamine levels in cases undergoing 
major and minor lower extremity amputations. Nine out of twelve cases who underwent 
major (Trans-tibial or trans-femoral) amputations had low thiamine levels as compared 
to six out of 12 patients with minor amputations who had low thiamine levels. But the 
difference between the two groups was not statistically significant with p value of 0.206. 
 
Age and low thiamine status 
Age Low thiamine Normal thiamine 
Less than 40 years 1 0 
More than 40 years 14 9 
 
The above table describes the distribution of low thiamine levels in cases with respect to 
their age. Fourteen subjects (62.5%) in the case group who were above 40 years of age 
and had low thiamine as compared to 9 cases with normal thiamine levels above 40 years 
of age. The above difference was not statistically significant with p value of 0.429. 
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Duration of diabetes  
Duration of diabetes 
Low 
thiamine 
Normal 
thiamine 
P Value 
Less than 10 years 8 5 
0.916 
More than 10 years 7 4 
 
 
The above table describes the distribution of low thiamine in the cases with respect to the 
duration of diabetes. Eight cases having diabetes less than 10 years had low thiamine as 
compared to 7 cases with diabetes more than 10 years. There was no statistical difference 
among these two groups (P value = 0.916). 
 
Mode of Diabetic Treatment and thiamine status 
Type of Treatment Low thiamine Normal thiamine P Value 
No treatment 1 1 
0.703 
Any treatment 14 8 
 
Type of Treatment Low thiamine Normal thiamine P value 
Only OHA 11 8 
0.364 
Only Insulin 4 1 
 
The above two tables depict the distribution of low thiamine status in cases with respect 
to the type of diabetic treatment taken by the cases. Fifty percent of patients, who were 
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not on any anti-diabetic treatment, had low thiamine levels whereas sixty four percent of 
patients on any form of anti-diabetic treatment (oral hypoglycaemic agents, insulin or 
both) had low thiamine levels. There was no significant difference among these two 
groups (P value= 0.703). Among cases taking anti-diabetic treatment, low thiamine was 
seen in eleven out of 19 patients on oral hypoglycaemic agents whereas four out of five 
patients taking insulin had low thiamine levels. There was no significant difference in 
these two treatment modalities with respect to thiamine status (P value= 0.364). 
 
Body mass index and thiamine status 
 
Body Mass Index (BMI) Low thiamine Normal Thiamine P Value 
Less than 25 5 3 
1.000 
More than 25 10 6 
 
The above table shows the distribution of body mass index and thiamine status. Sixty 
two percent of cases (5 out of 8) with body mass index less than 25, had low thiamine 
levels and similarly sixty two percent of cases with body mass index higher than 25 had 
low thiamine levels. There was no difference among these groups with respect to 
thiamine levels (P value = 1.000). 
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Glycosylated haemoglobin percentage and thiamine status 
 
HbA1c (%) Low thiamine Normal thiamine P value 
Less than 8 4 4 
0.371 
More than 8 11 5 
 
The above table describes the distribution of low thiamine levels with respect to the 
percentage of glycosylated haemoglobin (HbA1c) in the blood. Fifty percent of cases (4 
out of 8) with HbA1c less than 8% had low thiamine levels whereas sixty nine percent of 
cases with HbA1c more than 8 (describing poor glycaemic control) had low thiamine 
levels. The difference among these groups was not statistically significant (P value= 
0.371).  
 
Urinary Micro-albuminuria and thiamine status 
Urinary Micro-albumin 
(mcg/mg of Creatinine) 
Low thiamine Normal thiamine P Value 
Less than 30 2 3 
0.243 
More than 30 13 6 
 
The above table describes the distribution of low thiamine levels and urinary micro-
albumin. Only forty percent of cases (2 out of 5) with normal urinary micro-albumin 
levels had low thiamine whereas sixty eight percent of cases (13 out of 19) with 
abnormal urinary micro-albumin levels had low thiamine levels. This difference was not 
statistically significant (P value = 0.243) 
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Age and type of amputation 
Age ( years ) Major amputation Minor Amputation P value 
Less than 40 1 0 
0.307 
More than 40 11 12 
 
The above table shows the comparison of type of amputation with respect to age among 
the cases. Ninety two percent of cases (11 out of 12) who had undergone a major 
amputation were more than forty years of age whereas all cases who had undergone 
minor amputations were more than 40 years of age. The difference was not statistically 
significant (P value = 0.307). 
Duration of diabetes and type of amputation 
Duration of 
diabetes (years) 
Major 
amputation 
Minor 
Amputation 
P value 
Less than 10 7 6 
0.682 
More than 10 5 6 
 
Then above table displays the distribution of type of amputation with respect to the 
duration of diabetes. Fifty eight percent of cases who had undergone major amputations 
(7 out of 12) had diabetes for less than 10 years whereas the duration of diabetes was 
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evenly distributed in the cases that had undergone minor amputations. There was no 
statistical significance between these groups (P value = 0.682). 
Anti-diabetic Treatment and the type of amputation 
Type of 
Treatment 
Major 
Amputation 
Minor 
Amputation 
P Value 
No treatment 1 1 
1.000 
Any treatment 11 11 
 
Type of 
Treatment 
Major 
Amputation 
Minor 
Amputation 
P value 
Only OHAs 10 9 
0.615 
Only Insulin 2 3 
 
 
The above two tables display the distribution of the type of amputation with respect to 
the mode of anti-diabetic treatment. The type of amputation was evenly distributed 
among cases with and without diabetic treatment. Among the cases undergoing anti-
diabetic treatment, fifty two percent of cases (10 out of 19) on oral hypoglycemic drugs 
had a major amputation whereas forty percent of cases on insulin only (2 out of 5) had a 
major amputation. The difference in these groups was not statistically significant as 
depicted by the P values in the table.  
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Body mass index and type of amputation  
Body Mass 
index 
Major Amputation Minor Amputation P Value 
Less than 25 5 3 
0.386 
More than 25 7 9 
 
The above table displays the distribution of type of amputations with respect to the body 
mass index of the cases. Fifty eight percent of the cases (7 out of 12) who underwent a 
major amputation had a body mass index of more than 25 whereas seventy five percent 
of the cases (9 out of 12) who underwent minor amputations had a body mass index of 
more than 25. This difference was not statistically significant (P value= 0.386). 
 
Glycosylated haemoglobin percentage and type of amputation 
HbA1c (%) 
Major 
amputation 
Minor 
Amputation 
P Value 
Less than 8 4 4 
1.000 
8 or more 8 8 
 
The above table depicts the distribution of the type of amputation with respect to the 
glycaemic control of the patient. Equal number of patients undergoing major and minor 
amputations had glycosylated haemoglobin percentage less than eight and more than 
eight.  
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Urinary Micro-albumin and type of amputation 
Urinary Micro-albumin 
( mcg/mg of Creatinine) 
Major 
Amputation 
Minor 
Amputation 
P value 
Less than 30 1 4 
0.132 
More than 30 11 8 
 
The above table shows the distribution of major and minor amputations among cases with 
respect to the presence or absence of urinary micro-albinuria. Ninety two percent of cases 
who underwent major amputations (11 out of 12) had urinary micro-albuminuria whereas 
only sixty seven percent of cases (8 out of 12) who underwent minor amputations had 
abnormal urinary micro-albumin levels. This difference was however not statistically 
significant. (P value= 0.132)  
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Discussion 
A hospital based prospective case control study was done to include a total of 48 patients. 
The variables in the demographic and anthropometric data such as age, sex, patient weight, 
height, body mass index, duration of diabetes were equally distributed between the two 
groups of 24 patients each and were hence, comparable. Both the groups were similar with 
respect to their prevalence of co-morbid illnesses. 
In terms of erythrocyte transketolase levels, the mean value in the case arm was 78.18 x10
-3 
ng/ng whereas the mean erythrocyte transketolase levels in the control arm was 83.75x10
-3 
ng/ng but the difference was not statistically significant. A study done by Kursat Dabak T and 
his colleagues comparing thiamine levels among normal individuals, diabetics without foot 
lesions and diabetes with foot lesions, had given similar results(84). Multiple studies have 
shown low thiamine levels among diabetic individuals as compared to healthy controls, but 
none had compared the thiamine levels among diabetic patients with or without lower 
extremity amputations(9,10,13). The mean value among the controls (83.75x10
-3 
ng/ng) was 
considered as the lower limit of normal thiamine levels. With that assumption, sixty two 
percent of the cases had low thiamine levels. 
Low thiamine levels were analysed in the case group and compared to the demographic and 
anthropometric variables.  Sixty two percent of cases above the age of forty had low thiamine 
levels. There was no significant correlation of low thiamine status with duration of diabetes 
(p value=0.916), mode of treatment (p value=0.703) or body mass index (p value=1.00). 
Low thiamine levels were analysed in the case group and compared to the markers of 
glycaemic control. There was no significant association of low thiamine status with 
glycosylated haemoglobin percentage more than 8% (p value=0.371) or urinary micro-
albuminuria (p value=0.243).  
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The median neuropathy disability score among cases was 8 as compared to 4 in the control 
group and the difference was statistically significant with p value of less than 0.001. This was 
in agreement with the findings of „The North-West Diabetes Foot Care Study‟ which reported 
that Neuropathy disability score more than 6 was associated with significant risk of foot 
ulceration and subsequent amputation in diabetics(23).  
The median urinary micro-albumin among the cases was 70.5mcg/mg of creatinine as 
compared to17mcg/mg of creatinine in the control arm and the difference was statistically 
significant with p value of 0.001. A study published in the Indian journal of Nephrology 
deduced a prevalence of micro-albuminuria to be 14.2%(83). However in our current study, 
fifty four percent of recruited patients had urinary micro-albuminuria. Among the cases, 75% 
of patients had micro-albuminuria whereas only 33 percent of patients in the control arm had 
micro-albuminuria and the difference was statistically significant with p value of 0.003. 
Among the various components of metabolic syndrome, hypertension was noted to be the 
most common co-morbid condition among the subjects with twenty nine percent of the 
patients having hypertension.  
Longer duration of diabetes has been noted to be an independent risk factor of micro-vascular 
and macro-vascular complications of diabetes(81). The median duration of diabetes in the 
case group was more (10 years) as compared to the control group (8 years) which was in 
agreement to the aforementioned study but the difference was not statistically significant. 
Oral hypoglycaemic agents were noted to be the most common form of anti-diabetic 
treatment among cases and controls. Elevated Fasting and post prandial blood sugars have 
been associated with macro-vascular complications and cardiovascular disease associated 
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with diabetes mellitus(82). In this study, the median fasting and post prandial blood sugars 
were higher in the case group as compared to the control group ( cases- 176 and 272mg/dl 
and controls 155 and 241mg/dl) but the difference was not statistically significant.  
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CONCLUSION 
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The mean erythrocyte transketolase levels measured among the cases were lower 
than that for the control group but the difference was not statistically significant. Low 
thiamine levels were identified by using the mean value of the control arm as the lower 
limit of normal erythrocyte transketolase level. Using this value, sixty two percent of the 
cases were identified to have low thiamine levels. The low thiamine levels did not show 
any significant association with age, gender, body mass index or mode of diabetic 
treatment.  
The low thiamine levels were also compared to markers of glycaemic control and 
level of neuropathy among the cases. However, there was no significant correlation 
between the low thiamine levels and HbA1c, urinary micro-albumin and modified 
neuropathy disability score. Interestingly, the median neuropathy score among the cases 
(NDS=8) was significantly higher than that in the control arm (NDS=4). This was an 
important finding since a score of six or more was predictive of foot ulceration and 
subsequent risk of amputation, in the precious limb of the patients who had already 
undergone amputations of the contra-lateral limbs. Also the median urinary micro-
albumin among the cases (urine micro-albumin=70.5mg/mg of creatinine) was 
significantly higher than that among the controls (urine micro-albumin=17mg/mg of 
creatinine). The prevalence of abnormal urinary micro-albumin, suggestive of incipient 
diabetic nephropathy, was significantly high among cases (75%) as compared to the 
controls (33.3%). 
In view of the above, it is imperative that further role of thiamine should be 
investigated to establish a correlation between thiamine deficiency and complications of 
diabetes mellitus.  
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LIMITATION 
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The sample size calculated was 52 including 26 subjects in each arm. Despite 
recruiting 58 patients, only 48 samples were suitable for analysis of erythrocyte 
transketolase levels with 24 patients in each arm.  
Thiamine supplementation may have confounded the correlation between 
thiamine/ETKA levels and other parameters that were studied. 
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DATA SET 
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DATA COLLECTION SHEET 
 
I. Study Number       : 
II. Type of Subject (Case/Control)    : 
III. Name        : 
IV. Hospital Number      : 
V. Age        : 
VI. Duration of Diabetes      : 
VII. Diabetic Treatment (None/OHAs/Insulin)  : 
VIII. Other co morbidities     : 
Hypertension (yes/no)     : 
Ischemic Heart Disease (yes/no)   : 
Dyslipidemia (yes/no)     : 
IX. Alcohol intake (Units per week)    : 
X. Thiamine supplements in the last 6 months (Y/N) : 
XI. Height (in cm)       : 
XII. Weight (in Kg)      : 
XIII. Body Mass Index      : 
XIV. Type of Amputation (major/minor)   : 
XV. Neuropathy Disability Score    : 
XVI. Fasting Blood Sugar (mg/dl)     : 
XVII. Post-prandial Blood Sugar (mg/dl)    : 
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XVIII. HbA1c (%)       : 
XIX. Urine Micro-albumin     : 
XX. Serum Creatinine      : 
XXI. Erythrocyte Transketolase Activity    : 
XXII. Thiamine Pyrophosphate effect (%)    : 
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3. INFORMED CONSENT 
Study Title: A prospective case control study to compare the thiamine status in people with 
Type II Diabetes Mellitus undergoing lower limb amputations, and non-neuropathic Type II 
Diabetics 
Study Number: 
Participant’s name:  
Date of Birth / Age (in years): 
I_____________________________________________________________ 
___________, son/daughter of  ___________________________________ 
(Please tick boxes) 
Declare that I have read the information sheet provide to me regarding this study and have 
clarified any doubts that I had. [ ] 
I also understand that my participation in this study is entirely voluntary and that I am free to 
withdraw permission to continue to participate at any time without affecting my usual 
treatment or my legal rights [ ] 
I understand that I will receive free treatment for any study related injury or adverse event but 
I will not receive and other financial compensation [ ] 
I understand that the study staff and institutional ethics committee members will not need my 
permission to look at my health records even if I withdraw from the trial. I agree to this 
access [ ]  
I understand that my identity will not be revealed in any information released to third parties 
or published [ ]   
I voluntarily agree to take part in this study [ ] 
Name: 
Signature: 
Date: 
Name of witness: 
Relation to participant: 
Date: 
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Informed Consent - Hindi
111 
 
 
112 
 
Informed consent-Tamil
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Informed consent - Telugu
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4. Information sheet 
 
You are being requested to participate in a study to see if the levels of thiamine, a vitamin in 
your diet correlate with type II diabetes. A common complication of diabetes is nerve damage 
in the legs and feet which eventually puts you at risk of ulcer formation and possible 
amputation. Thiamine is a vitamin present in your diet and its deficiency is known to cause 
nerve damage as well. My study aims to seek a relation between nerve damage in diabetes 
and the thiamine status of your body. We hope to include about 80 people from this hospital 
in this study. 
What does Thiamine do? 
It is known that thiamine is an important part of digestion of the food we eat as well as 
functioning of our nervous system. There are certain factors which affect the levels of this 
vitamin in our body which include prolonged intake of alcohol or severe kidney damage. This 
decrease in thiamine affects nerves and their repair. 
What is the relation between thiamine and diabetes? 
We have observed that thiamine supplementation helps in the healing of ulcers in animals. 
We have also seen reduced thiamine levels in diabetic patients with kidney damage. 
Therefore we wish to see if there is a change in thiamine levels among people who have 
undergone an amputation of the lower limb due to diabetes and compare them with people 
who have diabetes but have no nerve damage or amputation. 
If you take part what will you have to do? 
If you agree to participate in this study, you will be asked a few questions about your age, 
duration of diabetes and the medications that you are using for diabetes and your height and 
weight will be measured. We will also be checking your feet for signs of nerve damage. We 
will also be collecting a single blood sample using standard precautions, to measure the 
thiamine levels. We will also be collecting information regarding some blood tests previously 
performed in this hospital, from the medical records system. 
All other treatments that you are already on will be continued and your regular treatment will 
not be changed during this study.  No additional procedures or blood tests will be conducted 
routinely for this study.  
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Can you withdraw from this study after it starts? 
Your participation in this study is entirely voluntary and you are also free to decide to 
withdraw permission to participate in this study. If you do so, this will not affect your usual 
treatment at this hospital in any way.  
What will happen if you develop any study related injury? 
We do not expect any injury to happen to you but if you do develop any side effects or 
problems due to the study, these will be treated at no cost to you. We are unable to provide 
any monetary compensation, however.  
Will you have to pay for the blood test?  
The blood test taken from you will be performed free of cost for the purpose of this study. 
Any other treatment that you usually take will continue but the usual arrangements that you 
have with the hospital will decide how much you pay for this.  
Will your personal details be kept confidential? 
The results of this study will be published in a medical journal but you will not be identified 
by name in any publication or presentation of results. However, your medical notes may be 
reviewed by people associated with the study, without your additional permission, should you 
decide to participate in this study.  
 
If you have any further questions, please ask Dr. Binoy Abraham, (tel: 0416 2282082/ 
+91 9994494055) or email: binoy@cmcvellore.ac.in/ docbinoy88@gmail.com  
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